Bill proposes risk plan for all approvals

Share this article:
Proposed drug safety legislation would require each new drug and biologic approved by the FDA to have a Risk Evaluation and Mitigation Strategy (REMS).

Senate Health, Education, Labor and Pensions Committee chairman Mike Enzi (R-WY) and ranking Democrat Edward Kennedy (MA) released details of their draft legislation: the Enhancing Drug Safety and Innovation Act of 2006.

Under the proposal, drug sponsors and the FDA would review the REMS at least annually for three years, as well as in applications for a new indication, when the sponsor suggests changes, or when the FDA requests a review. Sponsors would propose a REMS and the FDA would approve it after “structured negotiations.”

Enzi and Kennedy said the REMS is intended to be an integrated, flexible mechanism to acquire and adapt to new safety information about a drug. At a minimum, REMS would have to contain the FDA-approved professional labeling; 15-day, quarterly and annual reports of adverse events; a surveillance plan to assess known serious risks and to identify unexpected serious risks; and a timetable for periodic REMS assessment.

Increased drug user fees would be used to review REMS proposals and assessments and for FDA's general drug safety surveillance, according to the summary.

The legislation also calls for the creation of a clinical trials registry and a clinical trials results database to be maintained by the National Institutes of Health.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.